Hungarian drugmaker Richter Gedeon says that its full-year 2006 consolidated sales totaled 209.42 billion forint ($1.07 billion), a 21.3% rise on the previous year. The group's net profit reached 52.10 billoin forint, up 15%, as diluted earnings per share also rose 15%, to 2,795 forint per share. Operating profit surged 26.8% to 50.20 billion forint. Domestic sales fell 4% to 54.83 billion forint as exports jumped 33.9% to 154.59 billion forint. The Commonwealth of Independent States was the largest area of business growth and the biggest contributor to export sales, with income from this region up 50.7% to 65.60 billion forint. Exports to the USA jumped 31.7% to 19.11 billion forint, while sales to the European Union rose 20.5% to 47.70 billion forint.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze